[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360189-105":59,"doc-detail-360189-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","event-free-survival-as-a-surrogate-for-overall-survival-in-locally-advanced-esophageal-cancer-a-correlation-analysis-of-trials-assessing-definitive-chemoradiation-therapies","Event-free survival as a surrogate for overall survival in locally advanced esophageal cancer - a correlation analysis of trials assessing definitive chemoradiation therapies","","Assessing overall survival (OS) in oncology clinical trials often requires long follow-up, delaying evaluation of treatments for esophageal cancer. Event-free survival (EFS) has been proposed as a surrogate for OS, but its validity for definitive chemoradiotherapy (dCRT) in unresectable locally advanced disease remains unclear. This study evaluates trial-level correlations between EFS and OS using randomized controlled trials that report hazard ratios for both endpoints.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/event-free-survival-as-a-surrogate-for-overall-survival-in-locally-advanced-esophageal-cancer-a-correlation-analysis-of-trials-assessing-definitive-chemoradiation-therapies/360189/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/event-free-survival-as-a-surrogate-for-overall-survival-in-locally-advanced-esophageal-cancer-a-correlation-analysis-of-trials-assessing-definitive-chemoradiation-therapies/360189.png","ImageObject",300,407,{"name":92,"@type":93},"Terk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are surrogate endpoints needed in locally advanced esophageal cancer trials?","Question",{"text":112,"@type":113},"OS is considered the gold standard but often requires extended follow-up, delaying treatment evaluation. Surrogate endpoints like EFS can potentially speed access to effective therapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the relationship between EFS and OS assessed?",{"text":117,"@type":113},"The study used a systematic review of randomized controlled trials, extracting hazard ratios for EFS (or similar early endpoints) and OS. Weighted linear regression assessed correlation between log(HR) values, with robustness checked via leave-one-out cross-validation and sensitivity analyses.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the trial-level correlation analysis find?",{"text":121,"@type":113},"The analysis showed a strong EFS–OS correlation, with EFS significantly predicting OS. The association remained supported by leave-one-out cross-validation and sensitivity analyses, indicating EFS may function as a valid surrogate for OS in dCRT patients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360189,1790197471,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099525198933,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Xue et al. BMC Cancer (2026) 26:659 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-15914-6](https://doi.org/10.1186/s12885-026-15914-6)  \nRESEARCH Open Access  \nEvent-free survival as a surrogate for overall survival in locally advanced esophageal cancer: a correlation analysis of trials assessing definitive chemoradiation therapies  \nWeiguang Xue1, Adriana Valderrama2, Karthik Ramakrishnan2, Jenny Zhou1, Yan Meng1, Sonal Bordia2 and Manish A. Shah3*  \nAbstract  \nBackground Treatments for esophageal cancer are evolving rapidly, highlighting the need for surrogate endpoints to expedite patient access to therapy. Overall survival (OS) remains the gold standard endpoint in oncology clinical trials, but its assessment often requires extended follow-up, delaying treatment evaluations. Event-free survival (EFS) has emerged as a promising surrogate for OS in resectable locally advanced esophageal cancer. However, its validity in the context of definitive chemoradiotherapy (dCRT), the standard treatment for unresectable disease, has not been established. We assessed the trial-level correlation between EFS and OS in this setting.  \nMethods A systematic literature review identified randomized controlled trials (RCTs) evaluating dCRT for unresectable locally advanced esophageal cancer. Studies reporting hazard ratios (HRs) for both EFS (or similarly defined early endpoints) and OS were included. Weighted linear regression (WLR) was used to assess the correlation between log(HR) for EFS and log(HR) for OS. The strength of the correlation was evaluated using the coefficient of determination (R2), with thresholds of ≥ 0.65 or ≥ 0.75 indicating good surrogacy. The robustness ofthe WLR model and correlation analyses was confirmed by leave-one-out cross-validations and sensitivity analyses, respectively. Results Fourteen between-treatment comparisons from 11 RCTs (N = 2812) in unresectable locally advanced esophageal cancer were included. Eight studies were conducted in China and three in Europe, with sample size and follow-up ranging from 86 to 434 patients and 24 to 60 months, respectively. Reported median EFS was 17.5 months, whereas median OS was 25.1 months. Most patients had advanced-stage squamous cell carcinoma.  \nThe correlation analysis identified a strong EFS–OS correlation (estimated slope coefficient: 0 . 91; 95% confidence interval [CI], 0 .62–1. 20, P\u003C0 . 001; R2=0 . 80; 95% CI, 0 .38–0. 96), indicating that EFS was a significant predictor of OS. The leave-one-out cross-validation confirmed this association, with 71.4% of observed OS HRs falling within the predicted 95% CIs. Sensitivity analyses further supported the robustness of the correlation.  \n*Correspondence:  \nManish A. Shah [mas9313@med.cornell.edu](mas9313@med.cornell.edu)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.","cbCait9XMwVhLuIB","https://ap.wps.com/l/cbCait9XMwVhLuIB","pdf",1654063,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusions\n# Keywords","[{\"question\":\"Why are surrogate endpoints needed in locally advanced esophageal cancer trials?\",\"answer\":\"OS is considered the gold standard but often requires extended follow-up, delaying treatment evaluation. Surrogate endpoints like EFS can potentially speed access to effective therapy.\"},{\"question\":\"How was the relationship between EFS and OS assessed?\",\"answer\":\"The study used a systematic review of randomized controlled trials, extracting hazard ratios for EFS (or similar early endpoints) and OS. Weighted linear regression assessed correlation between log(HR) values, with robustness checked via leave-one-out cross-validation and sensitivity analyses.\"},{\"question\":\"What did the trial-level correlation analysis find?\",\"answer\":\"The analysis showed a strong EFS–OS correlation, with EFS significantly predicting OS. The association remained supported by leave-one-out cross-validation and sensitivity analyses, indicating EFS may function as a valid surrogate for OS in dCRT patients.\"}]","Event-free survival as a surrogate for overall survival in locally advanced esophageal cancer - a correlation analysis of trials assessing definitive chemoradiation therapies | PDF",1790139032,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da367505921ae61d458d0698251be487.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/65ddc1763e5b3acdb0edcbd5850246eb.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4620ba565d67b6483c4b1e5fe72e391.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/784cec57e12b93f24836953521150bda.webp",980,1306]